Communication of biomarker, genetic, lifestyle risk factor profiles for RA
RA 生物标志物、遗传、生活方式风险因素概况的交流
基本信息
- 批准号:8293776
- 负责人:
- 金额:$ 39.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAdoptionAir PollutionAllelesAttitudeAutoantibodiesBehaviorBehavioralBiological MarkersBreast Cancer Risk Assessment ToolClinical ResearchClinical TrialsCommunicationCommunication ToolsComprehensionCounselingDevelopmentDiagnosisDietDietary FactorsDiseaseEarly treatmentEducationEnvironmental Risk FactorEvolutionExogenous Hormone TherapyExposure toFirst Degree RelativeGeneral PopulationGeneticGenetic RiskGenetic screening methodHealth behaviorHealth behavior changeHealth educationHeart DiseasesHospitalsIndividualKnowledgeLife StyleMethodsModelingModificationNational Institute of Arthritis and Musculoskeletal and Skin DiseasesOral healthPamphletsPathogenesisPatientsPeriodontitisPersonal CommunicationPersonsPharmaceutical PreparationsPhasePopulationPredispositionPreventionPreventivePrintingRandomized Controlled TrialsReadabilityReadinessResearchRheumatoid ArthritisRiskRisk BehaviorsRisk FactorsSerumSilicon DioxideSmokingStagingSurveysTestingWomanarmbehavior changebehavior measurementcigarette smokingcomparison groupcytokinedisabilitygene environment interactiongenetic risk factorgenetic varianthigh riskinnovationlifestyle factorsliteracymalignant breast neoplasmmodifiable riskmultidisciplinarypost interventionpre-clinicalpreventrandomized trialwillingness
项目摘要
The identification of autoantibodies and cytokines in the serum many years prior to the diagnosis of rheumatoid arthritis (RA) suggests opportunities to prevent disease during the pre-clinical phase. Recent research has led to the recognition that RA develops in individuals with genetic risk factors after exposure to environmental factors, including cigarette smoking, periodontitis, and dietary factors. Having a first degree relative (FDR) with RA increases RA risk 3- to 9-fold compared to that in the general population. Despite the expanding knowledge of individual risk factors in the development of RA, there have been no studies of how best to communicate biomarker, genetic and lifestyle risk profiles for a given individual to enable personalized prevention of RA. Given the recent emergence of effective early treatment and the promise of preventive therapies, RA risk prediction now has the potential to avert decades of disability in at-risk patients. In this project, we will build upon our prior discoveries and risk models to develop an online RA risk calculator that combines biomarker, genetic and lifestyle factors. We will then conduct a randomized, controlled trial using this risk calculator in aymptomatic first degree relatives of RA patients in order to test the impact of risk education and counseling upon the readiness to adopt preventive health behaviors. We propose the following specific aims: 1) To develop an online RA risk calculator, a personalized communication tool that includes biomarker, genetic and lifestyle RA risk factors and 2) To conduct a randomized trial of communication of risk factor profiles to first degree relatives of RA patients to test whether use of risk prediction profiles and education will result in change in readiness to undertake behaviors to decrease their RA risk and health behavior change. We will conduct a 3-arm randomized trial, assigning 222 FDRs to receive: (i) a printed pamphlet, (ii) online risk communication or (iii) online risk communication plus health education and counseling. We will follow these groups at 6 weeks, 6 months and 12 months post intervention in order to determine change in behavioral readiness to modify smoking, oral health, or diet behaviors and health behavior change.
在诊断类风湿性关节炎(RA)之前多年,血清中自身抗体和细胞因子的鉴定表明在临床前阶段预防疾病的机会。最近的研究已经认识到,RA发生在暴露于环境因素(包括吸烟、牙周炎和饮食因素)后具有遗传风险因素的个体中。与一般人群相比,一级亲属(FDR)患RA的风险增加3至9倍。尽管对RA发展中的个体风险因素的认识不断扩大,但还没有研究如何最好地传达特定个体的生物标志物,遗传和生活方式风险特征,以实现RA的个性化预防。鉴于最近出现的有效的早期治疗和预防性治疗的承诺,RA风险预测现在有可能避免风险患者数十年的残疾。在这个项目中,我们将建立在我们先前的发现和风险模型的基础上,开发一个结合生物标志物,遗传和生活方式因素的在线RA风险计算器。然后,我们将使用该风险计算器在RA患者的一级亲属中进行随机对照试验,以测试风险教育和咨询对采取预防性健康行为的准备程度的影响。我们提出以下具体目标:1)开发一个在线RA风险计算器,一个个性化的沟通工具,包括生物标志物,遗传和生活方式RA风险因素和2)进行一项随机试验,向RA患者的一级亲属传达风险因素概况,以测试使用风险预测概况和教育是否会导致准备采取行为以降低RA风险的变化和健康行为的改变。我们将进行一项3组随机试验,分配222名FDR接受:(i)印刷小册子,(ii)在线风险沟通或(iii)在线风险沟通加健康教育和咨询。我们将在干预后6周、6个月和12个月对这些组进行随访,以确定改变吸烟、口腔健康或饮食行为的行为准备变化以及健康行为变化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ELIZABETH W KARLSON其他文献
ELIZABETH W KARLSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ELIZABETH W KARLSON', 18)}}的其他基金
eMERGE Phase IV Clinical Center at Partners HealthCare
Partners HealthCare 的 eMERGE IV 期临床中心
- 批准号:
10230561 - 财政年份:2020
- 资助金额:
$ 39.75万 - 项目类别:
A New England Enrollment Center for PMI Cohort Program
新英格兰 PMI 队列计划招生中心
- 批准号:
9453746 - 财政年份:2016
- 资助金额:
$ 39.75万 - 项目类别:
A New England Enrollment Center for PMI Cohort Program
新英格兰 PMI 队列计划招生中心
- 批准号:
9355397 - 财政年份:2016
- 资助金额:
$ 39.75万 - 项目类别:
EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE
PARTNERS HEALTHCARE 新兴三期临床中心
- 批准号:
9493516 - 财政年份:2015
- 资助金额:
$ 39.75万 - 项目类别:
eMERGE Phase IV Clinical Center at Mass General Brigham
麻省总医院布里格姆分校 eMERGE IV 期临床中心
- 批准号:
10625354 - 财政年份:2015
- 资助金额:
$ 39.75万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 39.75万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 39.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 39.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 39.75万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 39.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 39.75万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Standard Grant